AstraZeneca’s breakthrough in lung cancer treatment: Datopotamab deruxtecan achieves promising survival rates
AstraZeneca’s datopotamab deruxtecan (Dato-DXd), a cutting-edge TROP2-directed antibody-drug conjugate, has demonstrated encouraging overall survival results in the TROPION-Lung01 Phase III trial, which focused on patients with advanced nonsquamous non-small cell lung cancer (NSCLC). The study, conducted in collaboration with Daiichi Sankyo, compared datopotamab deruxtecan with docetaxel, the standard chemotherapy, revealing a median overall survival (OS) […]